ChartMill · Sep 17, 2026
Innoviva (NASDAQ:INVA): An Undervalued Value Stock Backed by Strong Cash Flow
Innoviva (INVA) scores 7/10 in the Decent Value screen, combining a cheap valuation with strong profitability, health and growth.
IN
NASDAQ · INVA
Innoviva, Inc.
Healthcare · Biotechnology
$20.98
Down-$0.06 (-0.29%)
Updated Sep 23, 2026, 5:32 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.33B
- P/E ratio
- 33.55
- Dividend yield
- 0.00%
- 52-week range
- $20.20 – $24.45
- Volume
- 931.64K
- Avg. volume
- 812.23K
Price performance
INVA price history
1M range · 20 trading sessions · Daily adjusted prices
INVA closed at $20.98 after 20 trading sessions, down 0.90% for the selected period.
- Last close
- $20.98
- Period change
- -0.90%
- Period low
- $20.62
- Period high
- $21.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $21.17 | $21.39 | $20.96 | $20.98 | 931.64K |
| Sep 21, 2026 | $21.10 | $21.27 | $21.00 | $21.04 | 688.52K |
| Sep 18, 2026 | $20.93 | $21.18 | $20.85 | $21.14 | 1.44M |
| Sep 17, 2026 | $21.22 | $21.415 | $21.00 | $21.05 | 1.25M |
| Sep 16, 2026 | $20.86 | $21.24 | $20.86 | $21.20 | 715.4K |
| Sep 15, 2026 | $20.86 | $20.88 | $20.50 | $20.84 | 1.1M |
| Sep 14, 2026 | $20.93 | $21.105 | $20.69 | $20.90 | 885.41K |
| Sep 11, 2026 | $20.84 | $20.875 | $20.45 | $20.66 | 727.35K |
| Sep 10, 2026 | $21.16 | $21.24 | $20.58 | $20.62 | 836.38K |
| Sep 9, 2026 | $21.16 | $21.405 | $20.77 | $21.13 | 847.36K |
| Sep 8, 2026 | $21.06 | $21.51 | $20.87 | $21.34 | 782.83K |
| Sep 4, 2026 | $21.20 | $21.36 | $21.09 | $21.33 | 563.51K |
| Sep 3, 2026 | $21.48 | $21.48 | $21.04 | $21.35 | 612.46K |
| Sep 2, 2026 | $21.27 | $21.48 | $21.215 | $21.35 | 600.6K |
| Sep 1, 2026 | $20.97 | $21.175 | $20.94 | $21.08 | 798.74K |
| Aug 31, 2026 | $20.97 | $21.05 | $20.68 | $20.77 | 877.33K |
| Aug 28, 2026 | $20.96 | $21.07 | $20.80 | $20.97 | 527.01K |
| Aug 27, 2026 | $20.99 | $21.095 | $20.8601 | $20.96 | 488.06K |
| Aug 26, 2026 | $21.15 | $21.33 | $20.84 | $21.24 | 693.03K |
| Aug 25, 2026 | $21.10 | $21.24 | $20.93 | $21.17 | 412.69K |
Latest INVA news
The latest Smart Investors Daily articles mentioning INVA.
Stock researchCompany · Overview
INVA research
Overview
Company profile and research snapshot.
Company profile
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 22, 2026 | BTIG | Buy | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | BTIG | Buy | — |
| May 7, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.
Benzinga · Aug 5, 2026
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
Innoviva (NASDAQ:INVA) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $0.40 by 385 percent. This is a 248.05 percent decrease over earnings of $0.77 per share from the same
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
